BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Study Evaluating the Value of Vendaje® Compared to the Standard of Care for Non-Healing Diabetic Foot Ulcers BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Study Evaluating the Value of Vendaje®

BioStem Technologies Reports Record Second Quarter 2024 Revenue of $74.5 Million BioStem Technologies Reports Record Second Quarter 2024 Revenue of $74.5 Million

BioStem Technologies to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024 BioStem Technologies to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024